Dronedarone for the Treatment of Non-Permanent Atrial Fibrillation (TA197)

Technology Appraisal Guidance No. 197

Source: National Institute for Health and Care Excellence

1 Guidance

1.1 Dronedarone is recommended as an option for the treatment of non-permanent atrial fibrillation only in people:

  • whose atrial fibrillation is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option, and
  • who have at least one of the following cardiovascular risk factors:
    - hypertension requiring drugs of at least two different classes
    - diabetes mellitus
    - previous transient ischaemic attack, stroke or systemic embolism
    - left atrial diameter of 50 mm or greater
    - left ventricular ejection fraction less than 40% (noting that the summary of product characteristics [SPC] does not recommend dronedarone for people with left ventricular ejection fraction less than 35% because of limited experience of using it in this group) or
    - age 70 years or older, and
  • who do not have unstable New York Heart Association (NYHA) class III or IV heart failure.

1.2 People who do not meet the criteria in section 1.1 who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA197

An abridged version of this guidance (a 'quick reference guide') is also available. Printed copies of the quick reference guide can be obtained by contacting 0845 003 7783 or emailing publications@nice.org.uk and quoting reference number N2274. It is also available on the Internet at http://guidance.nice.org.uk/TA197/QuickRefGuide/pdf/English

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Dronedarone for the treatment of non permanent atrial fibrillation
Issue Date: August 2010
Review Date: March 2013

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

MIMS launches Respiratory and Allergy Learning workshops 2019

MIMS launches Respiratory and Allergy Learning workshops 2019

Join us for the MIMS Workshops Respiratory and Allergy...

Hormone Replacement Therapy (HRT)

Hormone Replacement Therapy (HRT)

Hormone doses and costs of HRT preparations.

Widespread false diagnosis of COPD is exposing patients to unnecessary medication risks, study suggests
Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.